联合用药对新型隐球酵母菌脑膜脑炎治疗分析

Combination therapy in treatment of novel Cryptococcus meningoencephalitis

目的探讨联合用药治疗新型隐球酵母菌脑膜脑炎不良反应与合理性,以期提高临床治疗水平。方法随机选取2010年1月-2013年2月30例新型隐球酵母菌脑膜脑炎患者为研究对象,将其分为两组,各15例;对照组采用常规用药,观察组采用联合用药,分析两组患者的用药合理性及不良反应;所有数据采用SPSS13.0软件进行分析。结果两组患者治疗后在寒颤、高热比较差异无统计学意义,而在其他的不良反应的发生率比较差异有统计学意义(P<0.05),两组患者在住院费用和日均费用比较差异无统计学意义,而在住院天数、抗菌药物及激素使用比较则差异有统计学意义(P<0.05)。结论联合用药治疗新型隐球酵母菌脑膜脑炎的不良反应发生率低、用药合理。

OBJECTIVE To investigate the adverse reactions and rationality of combination therapy in treatment of novel Cryptococcus meningoencephalitis so as to raise the level of clinical treatment.METHODS A total of 30patients with novel Cryptococcus meningoencephalitis who were treated in the hospital from Jan 2010to Feb 2013were randomly recruited as the study objects and divided into two groups,with 15cases in each,then the control group was treated with the conventional drug therapy,the observation group was given the combination drug therapy,the rationality of drug therapy and the adverse reactions were observed and compared between the two groups,and all the data were statistically analyzed with the use of SPSS13.0software.RESULTS As compared with fever chills or high body temperature,the difference between the two groups was not significant,however,there was significant difference in the incidence of other adverse reactions（P〈0.05）.There was no significant difference in the hospitalization cost or daily cost between the two groups,but there was significant difference in the length of hospital stay and use of antibiotics or hormones between the two groups（P〈0.05）.CONCLUSION The combination therapy may contribute to low incidence of adverse reactions in treatment of novel Cryptococcus meningoencephalitis,with the medication reasonable.